The therapeutic potential of PD156707 and related butenolide endothelin antagonists

Bibliography

• YANAGISAWA M, KURIHARA H, KIMURA S et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411–415.
   PubMed Web of Science ®Google Scholar
• •Discovery of ET-1.
   Google Scholar
• INOUE A, YANAGISAWA M, KIMURA S et al: The human endothelin family: three structurally and pharmacol-ogy distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. ScL USA (1989) 86:2863–2867.
   PubMed Web of Science ®Google Scholar
• ARAI H, HORI S, ARAMORI I, OHKUBO H, NAKANISHI S: Cloning and expression of a cDNA encoding an endo-thelin receptor. Nature (1990) 348:730–732.
   PubMed Web of Science ®Google Scholar
• SAKURAI T, YANAGISAWA M, TAKUWA Y et al: Cloning of a cDNA encoding a non-isopeptide-selective sub-type of the endothelin receptor. Nature (1990) 348:732–735.
   PubMed Web of Science ®Google Scholar
• RUBANYI GM, POLOKOFF MA: Endothelins: molecularbiology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev. (1994) 46 (3):325–415.
   PubMed Web of Science ®Google Scholar
• DAVENPORT AP: Distribution of endothelin receptors.In: Endothelins in Biology and Medicine. Huggins JP, Pelton JT (Eds.), CRC Press, Inc., Florida, USA (1997):45–68.
   Google Scholar
• WEBB ML, MEEK TD: Inhibitors of endothelin. Medici-nal Res. Rev. (1997) 17(1):17–67.
   PubMed Web of Science ®Google Scholar
• DOHERTY AM, PATT WC, EDMUNDS JJ et al.: Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. J. Med. Chem. (1995) 38:1259–1263.
   PubMed Web of Science ®Google Scholar
• ••First disclosure of the structure and receptor selectivity ofPD156707.
   Google Scholar
• PATT WC, EDMUNDS JJ, REPINE JT et al.:Structure-activity relationships in a series of orally active y-hydroxy butenolide endothelin antagonists. J. Med. Chem. (1997) 40:1063–1074.
   PubMed Web of Science ®Google Scholar
• REYNOLDS EE, KEISER JA, HALEEN SJ et al.: Pharma-cological characterization of PD156707, an orally ac-tive ETA receptor antagonist. J. Pharmacol Exp. Ther. (1995) 273(3):1410–1417.
   PubMed Web of Science ®Google Scholar
• ••First report of the in vitro and in vivo activity of PD156707.
   Google Scholar
• WU-WONG JR, CHIOU WJ, HUANG Z-J, VIDAL MJ, OPGE-NORTH TJ: Endothelin receptors in human smooth muscle cells: antagonist potency differs on agonist evoked responses. Am. J. Physiol. (1994) 267:C1185–C1195.
   PubMed Web of Science ®Google Scholar
• MAGUIRE JJ, KUC RE, ROUS BA, DAVENPORT AP: Failureof BQ123, a more potent agonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments. Br. J. Pharmacol. (1996) 118:335–342.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, BARNES PJ, KAWIKOVA I, YACOUB MH,WARNER TD, BELVISI MG: Contraction of human air-way smooth muscle by endothelin-1 and IRL 1620: ef-fect of bosentan. Eur. J. Pharmacol (1997) 324:219–222.
   PubMed Web of Science ®Google Scholar
• REYNOLDS EE, HWANG O, FLYNN MA et al.: Pharma-cological differences between rat and human endothe-lin B receptors. Biochem. Biophys. Res. Commun. (1995) 209(2):506–512.
   PubMed Web of Science ®Google Scholar
• DOHERTY AM, PATT WC, REPINE J et al.: Structure-activity relationships of a novel series of orally active nonpeptide ETA and ETA/ETB receptor-selective an-tagonists. J. Cardiovasc. Pharmacol. (1995) 26\(Suppl. 3) :5358–S361.
   Google Scholar
• MAGUIRE JJ, KUC RE, DAVENPORT AP: Affinity and se-lectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ETA and ETB receptors. J. Phar-macol. Exp. Ther. (1997) 280:1102–1108.
   PubMed Web of Science ®Google Scholar
• •Human in vitro pharmacology of PD156707.
   Google Scholar
• IGNASIAK DP, MCCLANAHAN TB, SAGANEK U, POTOC-ZAK RE, HALLAK H, GALLAGHER KP: Effects of endothe-lin ETA receptor antagonism with PD156707 on hemodynamics and renal vascular resistance in rab-bits. Eur. J. Pharmacol (1997) 321:295–300.
   PubMed Web of Science ®Google Scholar
• WU-WONG JR, DIXON DB, OPGENORTH TJ: Effects ofhuman plasma proteins on endothelin binding and function. J. Cardiovasc. Pharmacol (1998) 31 (Suppl. 1):S164–S168.
   Google Scholar
• RODEHEFFER RJ, LERHMAN A, HEUBLIN DM, BURNETTJC, Jr.: Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clinic Proc. (1992) 67:719–724.
   Google Scholar
• WET C-M, LERMAN A, RODEHEFFER RJ et al.: Endothelinin human congestive heart failure. Circulation (1994) 89:1580–1586.
   PubMed Web of Science ®Google Scholar
• PACHER R, STANEK B, HULSMANN M et al.: Prognosticimpact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol. (1996) 27:633–641.
   PubMed Web of Science ®Google Scholar
• SAKAI S, MIYAUCHI T, SAKURAI T et al.: Endogenous endothelin-1 participates in the maintenance of car-diac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart. Circulation (1996) 93:1214–1222.
   PubMed Web of Science ®Google Scholar
• PICARD P, SMITH PJW, MONGE JC et al.: Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure. J. Cardiovasc. Pharmacol. (1998) 31 (Suppl. 1) :S294–S297.
   Google Scholar
• MOREAU P, D'USCIO LV, SHAW S, TAKASA H, BARTON M,LHSCHER TF: Angiotensin II increases tissue endothe-lin and induces vascular hypertrophy. Reversal by ETA-receptor antagonist. Circulation (1997) 96:1593–1597.
   PubMed Web of Science ®Google Scholar
• SHUBEITA HE, MCDONOUGH PM, HARRIS AN et al.: En-dothelin induction of inositol phospholipid hydroly-sis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J. Biol. Chem. (1990) 265:20555–20562.
   Google Scholar
• ITO H, HIRATA Y, HIROE M et al.: Endothelin-1 induceshypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyo-cytes. Circ. Res. (1991) 69:209–215.
   PubMed Web of Science ®Google Scholar
• MCCONNELL PI, WANG W, ZUCKER IH: Effects of anorally effective endothelin receptor antagonist in dogs with pacing-induced heart failure. Nebraska Med. J. (1996) 81:349–355.
   PubMedGoogle Scholar
• SPINALE FG, WALKER JD, MUKHERJEE R, IANNINI JP,KEEVER AT, GALLAGHER KP: Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Circulation (1997) 95:1918–1929.
   PubMed Web of Science ®Google Scholar
• SAKAI S, MIYAUCHI T, KOBAYASHI M, YAMAGUCHI I, GOTO K, SUGISHITA Y: Inhibition of myocardial endo-thelin pathway improves long-term survival in heart failure. Nature (1996) 384:353–355.
   PubMed Web of Science ®Google Scholar
• OHNISHI M, WADA A, TSUTAMOTO T et al.: Comparisonof therapeutic benefit with an endothelin-A receptor and a mixed endothelin receptor antagonist in heart failure. Circulation (1996) 94 (8) :P1545.
   PubMed Web of Science ®Google Scholar
• LOVE MP, FERRO CJ, HAYNES WG, WEBB DJ, MCMURRAYJJ: Selective or non-selective endothelin receptor blockade in chronic heart failure. Circulation (1996) 94(8):P425.
   PubMed Web of Science ®Google Scholar
• FRANCO-CERECEDA A: Endothelin- and neuropeptideY-induced vasoconstriction of human epicardial coro-nary arteries in vitro. Br. J. Pharmacol (1989) 97:968–972.
   PubMed Web of Science ®Google Scholar
• DAVENPORT AP, NUNEZ DJ, HALL JA, KAUMANN AJ, BROWN MJ: Autoradiographical localization of binding sites for porcine [12511-endothelin-1 in humans, pigs and rats: functional relevance in humans. J. Cardiovasc. Pharmacol. (1989) 13 (Suppl. 5) :S166–S170.
   Google Scholar
• GODFRAIND T: Evidence for heterogeneity of endothe-lin receptor distribution in human coronary artery. Br. J. Pharmacol. (1993) 101:1201–1205.
   Web of Science ®Google Scholar
• STAWSKI G, BANG OLSEN U, GRANDE P: Cytotoxic effectof endothelin-1 during 'simulated' ischemia in cul-tured rat myocytes. Eur. J. Pharmacol. (1991) 201:123–124.
   PubMed Web of Science ®Google Scholar
• MIYAUCHI T, YANAGISAWA M, TOMIZAWA T et al.: In-creased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet (1989) 2:53–54.
   PubMed Web of Science ®Google Scholar
• OMLAND T, LIE RT, AAKVAAG A, AARSLAND T, DICK-STEIN K: Plasma endothelin determination as a prog-nostic indicator of 1-year mortality after acute myocardial infarction. Circulation (1994) 89:1573–1579.
   PubMed Web of Science ®Google Scholar
• DAVENPORT AP, O'REILLY G, KUC RE: Endothelin ETAand ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br. J. Pharmacol. (1995) 114:1110–1116.
   PubMed Web of Science ®Google Scholar
• MAGUIRE JJ, DAVENPORT AP: ETA receptor-mediated constrictor responses to endothelin peptides in hu-man blood vessels in vitro. Br. J. Pharmacol. (1995) 115:191–197.
   PubMed Web of Science ®Google Scholar
• MOLENAAR P, O'REILLY G, SHARKEY A et al: Characteri-zation and localization of endothelin receptor sub-types in the human atrioventricular conducting system and myocardium. Circ. Res. (1993) 72:526–538.
   PubMed Web of Science ®Google Scholar
• BRUNNER F, OPIE LH: Role of endothelin-A receptors inischaemic contracture and reperfusion injury. Circula-tion (1998) 97:391–398.
   PubMed Web of Science ®Google Scholar
• KURIHARA H, YOSHIZUMI M, SUGIYAMA T et al.: Thepossible role of endothelin-1 in the pathogenesis of va-sospasm. J. Cardiovasc. Pharmacol. (1989) 13 (Suppl. 5):S132–S137.
   Google Scholar
• MAGUIRE JJ, DAVENPORT AP: PD156707: a potent an-tagonist of endothelin-1 in human diseased coronary arteries and vein grafts. J. Cardiovasc. Pharmacol. (1998) 31 (Suppl. 1) :S239–5240.
   Google Scholar
• MCCLANAHAN TB, MERTZ TE, IGNASIAK DP, JUNEAU PL,GALLAGHER KP: Effects of endothelin-receptor antago-nism with PD156707 on myocardial stunning in swine. J. Cardiovasc. Pharmacol. (1996) 28:679–686.
   PubMed Web of Science ®Google Scholar
• MERTZ TE, MCCLANAHAN TB, FLYNN MA et al.: Endothe-linA receptor antagonism by PD156707 does not re-duce infarct size after coronary artery occlusion/reperfusion in pigs. J. Pharmacol Exp. Ther. (1996) 278:42–49.
   PubMed Web of Science ®Google Scholar
• GROVER GJ, DZWONCZYK S, PARHAM CS: The endothelin-1 receptor antagonist BQ123 reduces in-farct size in a canine model of coronary occlusion and reperfusion. Cardiovasc. Res. (1993) 27:1613–1618.
   PubMed Web of Science ®Google Scholar
• BURKE SE, NELSON RA: Endothelin-receptor antagonist FR139317 reduces infarct size in a rabbit model when given before, but not after, coronary artery occlusion. J. Cardiovasc. Pharmacol. (1997) 29:87–92.
   PubMed Web of Science ®Google Scholar
• MCMURDO L, THIEMERMANN C, VANE JR: The effects of the endothelin ETA receptor antagonist, FR139317, on infarct size in a rat model of acute myocardial ische-mia and reperfusion. Br. J. Pharmacol. (1994) 112:75–80.
   PubMed Web of Science ®Google Scholar
• BARNES PJ, LIU SF: Regulation of pulmonary vascular tone. Pharmacol Rev. (1995) 47:87–131.
   PubMed Web of Science ®Google Scholar
• KIELY DG, CARGILL RI, STRUTHERS AD, LIPWORTH BJ: Cardiopulmonary effects of endothelin-1 in man. Car-diovasc. Res. (1997) 33:378–386.
   PubMed Web of Science ®Google Scholar
• CACOUB P, DORENT R, MAISTRE G et al.: Endothelin-1 in primary pulmonary hypertension and the Eisenmen-ger syndrome. Am. J. Cardiol. (1993) 71:448–450.
   PubMed Web of Science ®Google Scholar
• GIAID A, YANAGISAWA M, LANGLEBEN D et al.: Expres-sion of endothelin-1 in the lungs of patients with pul-monary hypertension. New Engl. J. Med. (1993) 328:1732–1739.
   PubMed Web of Science ®Google Scholar
• HAY DWP, LUTTMANN MA, HUBBARD WC, UNDEM BJ:Endothelin receptor subtypes in human and guinea-pig pulmonary tissues. Br. J. Pharmacol. (1993) 110:1175–1183.
   PubMed Web of Science ®Google Scholar
• FUKURODA T, KOBAYASHI M, OZAKI S et al.: Endothelinreceptor subtypes in human versus rabbit pulmonary arteries. J. Appl. Physiol. (1994) 76(5):1976–1982.
   PubMed Web of Science ®Google Scholar
• BUCHAN KW, MAGNUSSON H, RABE KF, SUMNER MJ, WATTS IS: Characterisation of the endothelin receptor mediating contraction of human pulmonary artery us-ing BQ123 and Ro 46-2005. Eur. J. Pharmacol. (1994) 260:221–225.
   PubMed Web of Science ®Google Scholar
• MCCULLOCH KM, DOCHERTY CC, MORECROFT I, MA-CLEAN MR: Endothelina receptor-mediated contrac-tion in human pulmonary resistance arteries. Br. J. Pharmacol. (1996) 119:1125–1130.
   PubMed Web of Science ®Google Scholar
• ZAMORA MA, DEMPSEY EC, WALCHAK SJ, STELZNER TJ:BQ123, an ETA antagonist, inhibits endothelin-1 medi-ated proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol. (1993) 9:429–433.
   PubMed Web of Science ®Google Scholar
• KEISER JA, SCHROEDER RL, HALLAK H, UPRICHARD ACG, DOHERTY AM, HALEEN SJ: Pharmacodynamics of PD156707, a selective endothelin receptor-A (ET-A) an-tagonist, in acute hypoxic pulmonary hypertension (PH). FASEB J (1997) 11(3):A36.
   Web of Science ®Google Scholar
• HALEEN S, SHROEDER R, WALKER D et al.: Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension. J. Cardiovasc. Pharmacol. (1998) 31 (Suppl. 1):S331–S335.
   Google Scholar
• SEIFERT V, LOFFLER B-M, ZIMMERMAN M, ROUX S, STOLKE D: Endothelin concentrations in patients with aneurysmal subarachnoid haemorrhage. J. Neurosurg. (1995) 82:55–62.
   PubMed Web of Science ®Google Scholar
• KITA T, KUBO K, SATO S, YONETANI Y, NARUSHIMA I,NAKASHIMA T: Contribution of endothelin-1 to disrup-tion of blood-brain barrier permeability in dogs. Naunyn-Schmiedeberg's Arch. Pharmacol (1998) 358\(No. 1, Suppl. 2):P2.12.
   Google Scholar
• PIERRE LN, DAVENPORT AP: Relative contribution ofendothelin A and endothelin B receptors to vasocon-striction in small arteries from human heart and brain. J. Cardiovasc. Pharmacol. (1998) 31\(Suppl. 1):S74–576.
   Google Scholar
• ZIV I, FLEMINDER G, DJALDETTI R, ACHIRON A,MELAMED E, SOKOLOVSKY M: Increased plasma endothelin-1 in acute ischaemic stroke. Stroke (1992) 23:1014–1016.
   PubMed Web of Science ®Google Scholar
• ADNER M, JANSEN I, EDVINSSON L: Endothelin-A recep-tors mediate contraction in human cerebral, menin-geal and temporal arteries. J. Autonomic Nervous System (1994) 49:S117–S121.
   PubMedGoogle Scholar
• PATEL TR, GALBRAITH S, GRAHAM DI, HALLAK H, DO-HERTY AM, McCULLOCH J: Endothelin receptor antago-nist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia. Cereb. Blood Flow Metab. (1996) 16:950–958.
   PubMed Web of Science ®Google Scholar